Company Filing History:
Years Active: 2019-2021
Title: Eamonn J O'Brien: Innovator in Molecular Diagnostics
Introduction
Eamonn J O'Brien is a notable inventor based in Hillsborough, GB. He has made significant contributions to the field of molecular diagnostics, particularly in cancer detection and treatment responsiveness. With a total of two patents to his name, O'Brien's work focuses on improving patient outcomes through innovative testing methods.
Latest Patents
O'Brien's latest patents include a molecular diagnostic test for cancer and a method of using a gene expression profile to determine cancer responsiveness to anti-angiogenic agents. The first patent provides methods and compositions for identifying cancer subtypes that exhibit changes in biomarker expression related to angiogenesis and vascular development. This test is designed to assess whether patients are clinically responsive or non-responsive to therapeutic regimens before administering anti-angiogenic agents. It can be applied across various cancer types and with different drugs that influence angiogenesis signaling. The second patent similarly focuses on identifying cancer subtypes responsive to anti-angiogenesis therapeutics, allowing for better classification of patients and prognostic indicators based on predictive markers.
Career Highlights
Throughout his career, Eamonn J O'Brien has worked with prominent companies such as Almac Diagnostics Limited and Almac Diagnostic Services Limited. His experience in these organizations has contributed to his expertise in molecular diagnostics and cancer research.
Collaborations
O'Brien has collaborated with notable colleagues, including Denis Paul Harkin and Fionnuala Patterson. These partnerships have likely enhanced his research and development efforts in the field of cancer diagnostics.
Conclusion
Eamonn J O'Brien's innovative work in molecular diagnostics has the potential to significantly impact cancer treatment and patient care. His patents reflect a commitment to advancing medical science and improving therapeutic outcomes for cancer patients.